STUDY OF TUMOR MARKERS IN BREAST AND OVARIAN CANCER PATIENTS

Screening for breast and ovarian cancers are required due to the late stage at diagnosis of cancer and poor survival. Serum CA125 and CA15-3 were important cancer detecting agents in patients with ovarian and breast cancers, respectively. CA15.3 and CA125, by itself, has been shown to be a usefully prognostic marker collectively with routine histopathological markers like tumor size, grade and stage in the management of breast cancer. The study (Breast cancer) was carried out on 25 subjects comparing 12 normal healthy volunteers and 13 patients of breast cancer with the range of 30-65years. The mean age of all breast cancers was 47.75 ± 3.19 years with minimum and maximum ages being 30 and 65 years respectively. The CA 15.3 values in serum ranged from 49.25-730.8 U/ml in the breast cancer group and 5.89-20.10 U/ml in control group. The study (Ovarian cancer) was carried out on 32 subjects comparing 13 normal healthy volunteers and 19 Patients of ovarian cancer with the range of 30-60years. The mean age of all ovarian cancers was 45 ± 2.0604 years with minimum and maximum ages being 30 and 60 years respectively. The CA 125 values in serum ranged from 40.6 – 59.028 U/ml in the ovarian cancer group and 5.89-20.15 U/ml in control group. The study demonstrated a correlation between the stage of breast cancer and ovarian cancer with CA 15.3 and CA125 positivity rate respectively. The higher the cancer stage, more likely that CA15.3 and CA125 will be elevated. The incidence of CA15.3 and CA125 in early stage disease indicates that it can be used in screening and diagnosis. It was also discovered that